Researchers associated with the Cancer Genome Atlas (TCGA) Research Network will publish more than 25 papers this week to discuss findings from the initiative.
The company plans to launch the system this summer in Europe, aiming to broaden cell-free DNA screening for trisomy 21, 18, and 13.
The suit alleges that Natera's Panorama test infringes US Patent No. 9,493,831 patent, which covers sequencing library preparation methods applied to maternal blood samples.
The company is now seeking commercial partners in Brazil to make the Iona test available in the country.
Adam Wolfberg argued that while corporate conflicts are widely discussed, physicians also have financial conflicts that can bias them against new technology.
The China Food and Drug Administration had also previously accredited both the NIFTY test and the BGISEQ sequencing platform.
The Chinese Academy of Sciences-led team said the approach could lead to a therapeutic strategy for human aneuploidy diseases involving additional chromosomes.
In a study involving almost 23,000 women, DNA reflex testing detect 95 percent of trisomies while avoiding recalls.
Denmark-based Arcedi would like to commercialize its technology through a major diagnostic company.
Several commercial NIPT providers in the US said they are planning to participate in the new program.
A new analysis examines the gender gap among paper authors in the sciences and says it may take decades or more to close.
Researchers have uncovered signals of selection that may enable the Bajau people to free five hundreds of feet deep, Reuters reports.
In Science this week: paternally inherited cis-regulatory structural variants in autism, and more.
A new report outlines issues facing the implementation of personalized medicine in the UK, the Independent reports.